Please login to the form below

Not currently logged in
Email:
Password:

Bayer veteran joins Aurinia as CEO

Stephen Zaruby spent 20 years at German pharma company
Aurinia Stephen Zaruby

Aurinia Pharmaceuticals has appointed Stepen Zaruby as president and CEO.

His career includes a 20-year stint at German company Bayer, including spells managing its domestic and international anti-infectives, quinolone and hospital/surgical business franchises.

Mmost recently he served as president at ZymoGenetics until its acquisition by Bristol-Myers Squibb in 2010. Since then he has worked as an independent consultant in life sciences.

Commenting on his latest appointment, Zaruby said he was looking forward to the future for kidney-focused Aurinia as it looks to launch its first drug.

“Aurinia is well positioned to bring voclosporin forward as an important new treatment for lupus nephritis,” he said.

Aurinia's chair Dr Richard Glickman said: “Stephen is a seasoned leader with a strong track record of delivering strategic direction and operational excellence to both established and emerging life sciences companies.

“He is exceptionally qualified to help us build our voclosporin franchise and sharpen our execution."

11th November 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics